Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom. Show more
12 Hammersmith Grove, London, W6 7AP, United Kingdom
Market Cap
325.9M
52 Wk Range
$1.97 - $7.83
Previous Close
$6.90
Open
$7.50
Volume
432,822
Day Range
$7.00 - $7.91
Enterprise Value
181.4M
Cash
102.2M
Avg Qtr Burn
-10.89M
Insider Ownership
24.38%
Institutional Own.
39.92%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Zerlasiran (SLN360) (siRNA Inhibitor) Details Cardiovascular Disease Due To High Lp(a) | Phase 3 Initiation | |
Divesiran Details Polycythemia Vera | Phase 2 Data readout | |
SLN312 (ANGPTL3 Inhibitor) Details Dyslipidemia | Phase 1 Data readout |